Miscommunicating Risk: The Byetta Disconnect
This article was originally published in The Pink Sheet Daily
Executive Summary
Disconnect between level of warning FDA chose and financial markets’ reaction is an object lesson in the risks of risk communication.
You may also be interested in...
Groundhog Day For Byetta, GLP-1 Class: Is Regulatory Winter Nearly Over?
Sponsors of GLP-1 diabetes therapies and their investors are eagerly awaiting spring for greater clarity about the prospects of the antidiabetic class
Groundhog Day For Byetta, GLP-1 Class: Is Regulatory Winter Nearly Over?
Sponsors of GLP-1 diabetes therapies and their investors are eagerly awaiting spring for greater clarity about the prospects of the antidiabetic class
Amylin, Lilly Partnership Tested By Lilly GLP-1 Project
Amylin expects to discuss changes to its partnership agreement with Lilly if Lilly's internal GLP-1 antidiabetic compound LY2189265 continues to progress in the clinic